Giovanni De Manzoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giovanni De Manzoni has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Gian Luca Baiocchi
General Surgery Unit, ASST Cremona, Cremona, Italy
75 shared publications - Uberto Fumagalli
Digestive Surgery, European Institute of Oncology, IRCCS, Milano, Italy
75 shared publications - Claudia Orrù
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
73 shared publications - Cristina Migliore
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
73 shared publications - Daniela Conticelli
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
73 shared publications - Filippo Pietrantonio
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
73 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (9) , 111928
Bridging prediction and reality: AI-based external validation of predictive models for lymph node metastasis in gastric cancer
- 13 June 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (9) , 111928
Open AccessBridging prediction and reality: AI-based external validation of predictive models for lymph node metastasis in gastric cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 gene knock-out abrogates responsiveness to olaparib in CAPAN-1 cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 gene knock-out abrogates responsiveness to olaparib in CAPAN-1 cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
LOF mutations and clinical characteristics of patients carrying HR gene variants
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
LOF mutations and clinical characteristics of patients carrying HR gene variants
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HR gene mutations in GEA models used in in vitro and in vivo experiments.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HR gene mutations in GEA models used in in vitro and in vivo experiments.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HRD and mutational signature scores in PDXs used in the preclinical trials
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HRD and mutational signature scores in PDXs used in the preclinical trials
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
BRCA2 LOF mutations in the GEA PDX models used in pre-clinical trials.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
BRCA2 LOF mutations in the GEA PDX models used in pre-clinical trials.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Microsatellite instability (MSI) evaluation in the GTR0264 and GTR0324 tumors.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Microsatellite instability (MSI) evaluation in the GTR0264 and GTR0324 tumors.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 KO cells do not display MSI.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 KO cells do not display MSI.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
RAD51 assay predicts PARPi response in Gastric Cancer PDX models.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
RAD51 assay predicts PARPi response in Gastric Cancer PDX models.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
A gastric cancer PDX model carrying two LOF mutations in the ATM gene is not responsive to olaparib.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
A gastric cancer PDX model carrying two LOF mutations in the ATM gene is not responsive to olaparib.